Drug Profile
MTBVAC
Alternative Names: MTBVAC 01Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator University of Zaragoza
- Developer Biofabri; Stellenbosch University; TuBerculosis Vaccine Initiative; University of Cape Town; University of Kwazulu Natal; University of Zaragoza
- Class Attenuated vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Tuberculosis
Most Recent Events
- 22 Feb 2024 University of Zaragoza in collaboration with International AIDS Vaccine Initiative and Biofabri plans a phase II trial for Tuberculosis (Prevention, In adolescents, In adults) (Intradermal), in September 2024 (NCT06272812)
- 30 Jan 2024 Phase-II clinical trials in Tuberculosis (In adolescents, In adults, Prevention) in South Africa (Intradermal) (NCT05947890)
- 17 Jul 2023 HIV Vaccine Trials Network plans a phase IIa HVTN605A5421 trial for Tuberculosis (Prevention, In adolescents, In adults) in South Africa (Intradermal, Injection) (NCT05947890)